Obesity pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.
ClassNone selected
MechanismNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
299 of 2118 arms with a reported figure. Choose arms to narrow the chart.
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- Semaglutide 2.4 mg
- Semaglutide Semaglutide placebo
- Semaglutide 7.2 mg
- Semaglutide Placebo
- Semaglutide 15 mg
- Semaglutide 2.4 mg
- Semaglutide Semaglutide
- Semaglutide Placebo (semaglutide)
- Semaglutide 2.4 mg
- Semaglutide 2.4 mg
- Semaglutide Semaglutide
- Semaglutide Placebo
- Semaglutide 2.4 mg
- Semaglutide Placebo
- Semaglutide Semaglutide, on treatment
- Semaglutide Placebo, on treatment
- Tirzepatide Placebo
- Tirzepatide 15 mg
- Tirzepatide 15 mg
- Tirzepatide Placebo
- Tirzepatide 10 mg
- Tirzepatide Tirzepatide MTD
- Tirzepatide Placebo
- Tirzepatide Tirzepatide
- Tirzepatide Placebo
- Tirzepatide 15 mg
- Tirzepatide Placebo
- Tirzepatide 10 mg
- Tirzepatide 15 mg
- Tirzepatide Placebo
- Tirzepatide 10 mg
- Orforglipron Placebo
- Orforglipron 6 mg
- Orforglipron 12 mg
- Orforglipron Placebo QD
- Orforglipron 6 mg
- Orforglipron 12 mg
- Survodutide 0.6 mg
- Survodutide Placebo group
- Survodutide 2.4 mg
- Survodutide 3.6 mg
- Survodutide 4.8 mg
- Exenatide Group A
- Exenatide Group B
- Liraglutide Liraglutide Placebo, Pre-diabetes
- Liraglutide 3.0 mg
- Liraglutide 3.0 mg
- Liraglutide 1.8 mg
- Liraglutide Placebo
- Liraglutide 3.0 mg
- Liraglutide Placebo
- Liraglutide 3.0 mg
- Liraglutide Placebo
- Liraglutide 3.0 mg
- Liraglutide Placebo, in trial
- Liraglutide 0.05 mg
- Liraglutide 0.1 mg
- Liraglutide 0.2 mg
- Liraglutide 0.3 mg
- Liraglutide 0.4 mg
- Liraglutide 3.0 mg
- Liraglutide Placebo + Metformin
- Liraglutide 100 mcg
- Liraglutide 200 mcg
- Liraglutide 300 mcg
- Liraglutide 2.4 mg
- Liraglutide 4.5 mg
- Liraglutide 1.2 mg
- Liraglutide 0.6 mg
- Liraglutide 0.3 mg
- Liraglutide 3.0 mg
- Lixisenatide Lixisenatide
- Lixisenatide Sitagliptin
- CT-868 CT-868 Placebo
- CT-868 1.8 mg
- CT-868 4.1 mg
- CT-868 6.6 mg
- Bimagrumab 30 mg
- Bimagrumab 30 mg
- Bimagrumab 30 mg
- Bimagrumab 1.0 mg
- Bimagrumab 2.4 mg
- Bimagrumab 1.0 mg
- Bimagrumab 2.4 mg
- Naltrexone And Bupropion NB16
- Naltrexone And Bupropion NB32
- Naltrexone And Bupropion Placebo
- Naltrexone And Bupropion NB32
- Naltrexone And Bupropion Placebo
- Naltrexone And Bupropion NB32
- Naltrexone And Bupropion Placebo
- Naltrexone And Bupropion NB32
- Naltrexone And Bupropion Placebo
- Phentermine And Topiramate VI-0521 Low
- Phentermine And Topiramate VI-0521 Top
- Phentermine And Topiramate Placebo
- Phentermine And Topiramate VI-0521 Top
- Phentermine And Topiramate VI-0521 Mid
- Phentermine And Topiramate TPM 46
- Phentermine And Topiramate TPM 92
- Phentermine And Topiramate PHEN 7.5
- Phentermine And Topiramate PHEN 15
- Phentermine And Topiramate Placebo
- Setmelanotide Placebo
- Setmelanotide Setmelanotide
- Setmelanotide Pivotal Cohort
- Setmelanotide Setmelanotide
- Setmelanotide Setmelanotide
- Setmelanotide Setmelanotide
- Setmelanotide Placebo
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide 2.4 mg | 83.5% | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo | 31.1% | n/r | n/r | n/r |
| Semaglutide 7.2 mg | 88.7% | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | 38.3% | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r |
| Semaglutide 1.0 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo I/II | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | n/r | n/r | n/r | n/r |
| Semaglutide 15 mg | n/r | 87.7% | 71.7% | 55% |
| Semaglutide 2.4 mg | n/r | 66.7% | 45% | 31.1% |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo OW | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | n/r | n/r | n/r | n/r |
| Semaglutide Insuline glargine U100 (reduced) + semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Insuline glargine U100 (titrated) | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | 34.1% | 56.1% | 76.4% |
| Semaglutide Placebo (semaglutide) | n/r | 90.5% | 97.9% | 99.6% |
| Semaglutide 7.2 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | 87% | 70.4% | 47.8% | 23.3% |
| Semaglutide 2.4 mg | 29.2% | 9.2% | 2.5% | 0% |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide 1.7 mg | n/r | n/r | n/r | n/r |
| Semaglutide 1.7 mg | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, in trial | n/r | n/r | n/r | n/r |
| Semaglutide Placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide) | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide | 72.5% | 61.8% | 53.4% | 37.4% |
| Semaglutide Placebo | 17.7% | 8.1% | 4.8% | 3.2% |
| Semaglutide 2.4 mg | 96% | n/r | n/r | n/r |
| Semaglutide Placebo | 12% | n/r | n/r | n/r |
| Semaglutide Semaglutide, on treatment | 92% | n/r | n/r | n/r |
| Semaglutide Placebo, on treatment | 12% | n/r | n/r | n/r |
| Tirzepatide Placebo | 34.5% | n/r | n/r | n/r |
| Tirzepatide 5 mg | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mg | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | 90.9% | n/r | n/r | n/r |
| Tirzepatide 15 mg | 86.41% | 69.58% | 51.78% | 33.98% |
| Tirzepatide Placebo | 30.55% | 8.68% | 2.57% | 0.96% |
| Tirzepatide 10 mg | 81.55% | 63.43% | 41.42% | 22.98% |
| Tirzepatide Tirzepatide (lead-in) | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD | 98.49% | n/r | n/r | n/r |
| Tirzepatide Placebo | 69% | n/r | n/r | n/r |
| Tirzepatide Tirzepatide | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide | 94.37% | 88.03% | 73.94% | 54.93% |
| Tirzepatide Placebo | 10.65% | 4.81% | 2.06% | 1.03% |
| Tirzepatide Tirzepatide MTD_GPI1 | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo_GPI1 | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD_GPI2 | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo_GPI2 | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mg | 96.05% | 92.11% | 82.89% | n/r |
| Tirzepatide Placebo | 20% | 4% | 1.33% | n/r |
| Tirzepatide 10 mg | 94.37% | 85.92% | 63.38% | n/r |
| Tirzepatide 15 mg | 92.65% | 83.82% | 72.06% | n/r |
| Tirzepatide Placebo | 29.41% | 14.71% | 2.94% | n/r |
| Tirzepatide 10 mg | 91.43% | 70% | 48.57% | n/r |
| Orforglipron Placebo | 24.4% | 7% | 1.9% | n/r |
| Orforglipron 6 mg | 49.8% | 23.9% | 7.3% | n/r |
| Orforglipron 12 mg | 60.2% | 35.5% | 17.7% | n/r |
| Orforglipron Placebo QD | 15% | 3.33% | 0% | 0% |
| Orforglipron 6 mg | 45.9% | 18.03% | 9.84% | 3.28% |
| Orforglipron 12 mg | 61.4% | 35.09% | 22.81% | 12.28% |
| Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg | n/r | n/r | n/r | n/r |
| Cagrilintide/semaglutide Placebo s.c. | n/r | n/r | n/r | n/r |
| Retatrutide 4 mg | n/r | n/r | n/r | n/r |
| Retatrutide 9 mg | n/r | n/r | n/r | n/r |
| Retatrutide 12 mg | n/r | n/r | n/r | n/r |
| Retatrutide Placebo | n/r | n/r | n/r | n/r |
| Survodutide 3.6 mg | n/r | n/r | n/r | n/r |
| Survodutide 6.0 mg | n/r | n/r | n/r | n/r |
| Survodutide Placebo | n/r | n/r | n/r | n/r |
| Survodutide 0.6 mg | 60.7% | 33.9% | 12.5% | n/r |
| Survodutide Placebo group | 25.9% | 11.1% | 5.6% | n/r |
| Survodutide 2.4 mg | 81% | 65.5% | 37.9% | n/r |
| Survodutide 3.6 mg | 82% | 65.6% | 45.9% | n/r |
| Survodutide 4.8 mg | 82.8% | 68.8% | 54.7% | n/r |
| VK2735 2.5 mg | n/r | n/r | n/r | n/r |
| VK2735 15 mg | n/r | n/r | n/r | n/r |
| VK2735 Placebo 13 weeks | n/r | n/r | n/r | n/r |
| Eloralintide Placebo | n/r | n/r | n/r | n/r |
| Eloralintide 1 mg | n/r | n/r | n/r | n/r |
| Eloralintide 3 mg | n/r | n/r | n/r | n/r |
| Eloralintide 6 mg | n/r | n/r | n/r | n/r |
| Eloralintide 9 mg | n/r | n/r | n/r | n/r |
| Berobenatide Placebo | n/r | n/r | n/r | n/r |
| Dulaglutide Dulaglutide Arm | n/r | n/r | n/r | n/r |
| Dulaglutide Placebo Arm | n/r | n/r | n/r | n/r |
| Exenatide Group A | n/r | n/r | n/r | n/r |
| Exenatide Group B | n/r | n/r | n/r | n/r |
| Exenatide Exenatide | n/r | n/r | n/r | n/r |
| Exenatide Placebo | n/r | n/r | n/r | n/r |
| Exenatide Exenatide once weekly (EQW ) | n/r | n/r | n/r | n/r |
| Exenatide Dapagliflozin (DAPA) | n/r | n/r | n/r | n/r |
| Exenatide EQW plus DAPA | n/r | n/r | n/r | n/r |
| Exenatide Dapagliflozin plus Glucophage (MET ER) | n/r | n/r | n/r | n/r |
| Exenatide Phentermine /Topiramate (PHEN/ TPM) ER | n/r | n/r | n/r | n/r |
| Exenatide Exenatide once weekly extended-release | n/r | n/r | n/r | n/r |
| Exenatide Matching placebo | n/r | n/r | n/r | n/r |
| Exenatide Group A | 31.5% | n/r | n/r | n/r |
| Exenatide Group B | 16.5% | n/r | n/r | n/r |
| Liraglutide 3.0mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Placebo, no Pre-diabetes | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Placebo, Pre-diabetes | 23.7% | 10.6% | n/r | n/r |
| Liraglutide 3.0 mg | 49.6% | 33.1% | n/r | n/r |
| Liraglutide 3.0 mg | 49.9% | 23.4% | n/r | n/r |
| Liraglutide 1.8 mg | 35.6% | 14.4% | n/r | n/r |
| Liraglutide Placebo | 13.8% | 4.3% | n/r | n/r |
| Liraglutide 3.0 mg | 50.5% | 26.1% | n/r | n/r |
| Liraglutide Placebo | 21.9% | 6.3% | n/r | n/r |
| Liraglutide 3.0 mg | 51.8% | 22.77% | n/r | n/r |
| Liraglutide Placebo | 23.98% | 6.55% | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r |
| Liraglutide Semaglutide | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Placebo (liraglutide) | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | 61.47% | 30.45% | 18.11% | n/r |
| Liraglutide Placebo, in trial | 38.82% | 19.75% | 8.92% | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r |
| Liraglutide Metformin XR plus liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Metformin XR plus placebo | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide Pen Injector (Saxenda) | n/r | n/r | n/r | n/r |
| Liraglutide Placebo liraglutide pen injector | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide | n/r | n/r | n/r | n/r |
| Liraglutide Placebo | n/r | n/r | n/r | n/r |
| Liraglutide 0.05 mg | 53.5% | 18.94% | n/r | n/r |
| Liraglutide 0.1 mg | 67.49% | 36.57% | n/r | n/r |
| Liraglutide 0.2 mg | 74.91% | 55.95% | n/r | n/r |
| Liraglutide 0.3 mg | 80.52% | 57.76% | n/r | n/r |
| Liraglutide 0.4 mg | 82.52% | 64.61% | n/r | n/r |
| Liraglutide 3.0 mg | 66.12% | 33.98% | n/r | n/r |
| Liraglutide Placebo + Metformin | 3% | n/r | n/r | n/r |
| Liraglutide Liraglutide + Metformin | n/r | n/r | n/r | n/r |
| Liraglutide 100 mcg | 18% | n/r | n/r | n/r |
| Liraglutide 200 mcg | 65% | n/r | n/r | n/r |
| Liraglutide 300 mcg | 92% | n/r | n/r | n/r |
| Liraglutide 2.4 mg | 74.12% | 43.97% | n/r | n/r |
| Liraglutide 4.5 mg | 88.74% | 53.49% | n/r | n/r |
| Liraglutide 1.2 mg | 75.84% | 35.79% | n/r | n/r |
| Liraglutide 0.6 mg | 61.98% | 24.06% | n/r | n/r |
| Liraglutide 0.3 mg | 57.47% | 15.28% | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | 76.16% | 39.43% | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r |
| Liraglutide Orlistat | n/r | n/r | n/r | n/r |
| Lixisenatide Lixisenatide | 18.4% | n/r | n/r | n/r |
| Lixisenatide Sitagliptin | 11.9% | n/r | n/r | n/r |
| Mazdutide 3/6 Milligrams (mg) Mazdutide | n/r | n/r | n/r | n/r |
| Mazdutide 10 mg | n/r | n/r | n/r | n/r |
| Mazdutide 16 mg | n/r | n/r | n/r | n/r |
| Mazdutide Placebo | n/r | n/r | n/r | n/r |
| Mazdutide 6 mg | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide placebo | n/r | n/r | n/r | n/r |
| Oral Semaglutide 25 mg | n/r | n/r | n/r | n/r |
| Oral Semaglutide Oral semaglutide placebo | n/r | n/r | n/r | n/r |
| Oral Semaglutide 50 mg | n/r | n/r | n/r | n/r |
| Oral Semaglutide oral semaglutide placebo once daily | n/r | n/r | n/r | n/r |
| TERN-601 250 mg | n/r | n/r | n/r | n/r |
| TERN-601 500 mg | n/r | n/r | n/r | n/r |
| TERN-601 750 mg | n/r | n/r | n/r | n/r |
| TERN-601 Matching Placebo | n/r | n/r | n/r | n/r |
| CT-868 CT-868 Placebo | 2% | n/r | n/r | n/r |
| CT-868 1.8 mg | 6% | n/r | n/r | n/r |
| CT-868 4.1 mg | 15% | n/r | n/r | n/r |
| CT-868 6.6 mg | 15% | n/r | n/r | n/r |
| HM15211 HM15211 | n/r | n/r | n/r | n/r |
| HM15211 Placebo | n/r | n/r | n/r | n/r |
| Pramlintide Placebo-P + Placebo-M | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mg | n/r | n/r | n/r | n/r |
| Pramlintide 2.5 mg | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mg | n/r | n/r | n/r | n/r |
| Pramlintide 1.25 mg | n/r | n/r | n/r | n/r |
| Pramlintide 2.5 mg | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mg | n/r | n/r | n/r | n/r |
| Pramlintide 1 | n/r | n/r | n/r | n/r |
| Pramlintide 2 | n/r | n/r | n/r | n/r |
| Pramlintide 3 | n/r | n/r | n/r | n/r |
| Pramlintide Placebo | n/r | n/r | n/r | n/r |
| Pramlintide Pramlintide + Metreleptin | n/r | n/r | n/r | n/r |
| Pramlintide Pramlintide Acetate and Placebo | n/r | n/r | n/r | n/r |
| Pramlintide Lead-In Period | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mg | 40% | n/r | n/r | n/r |
| Bimagrumab 30 mg | 58.1% | n/r | n/r | n/r |
| Bimagrumab 30 mg | 97.7% | n/r | n/r | n/r |
| Bimagrumab 1.0 mg | 73.3% | n/r | n/r | n/r |
| Bimagrumab 2.4 mg | 92.2% | n/r | n/r | n/r |
| Bimagrumab 1.0 mg | 97.6% | n/r | n/r | n/r |
| Bimagrumab 2.4 mg | 100% | n/r | n/r | n/r |
| Naltrexone And Bupropion NB16 | 39.49% | 20.17% | n/r | n/r |
| Naltrexone And Bupropion NB32 | 47.98% | 24.63% | n/r | n/r |
| Naltrexone And Bupropion Placebo | 16.44% | 7.44% | n/r | n/r |
| Naltrexone And Bupropion NB32 | 50.48% | 27.27% | n/r | n/r |
| Naltrexone And Bupropion Placebo | 17.11% | 7.02% | n/r | n/r |
| Naltrexone And Bupropion NB32 | 66.39% | 41.49% | n/r | n/r |
| Naltrexone And Bupropion Placebo | 42.49% | 20.21% | n/r | n/r |
| Naltrexone And Bupropion NB32 | 44.53% | 18.49% | n/r | n/r |
| Naltrexone And Bupropion Placebo | 18.87% | 5.66% | n/r | n/r |
| Naltrexone And Bupropion BWL + NB medication | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + Placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + Placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB medication | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone+Bupropion Medication | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone/Bupropion | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Placebo | n/r | n/r | n/r | n/r |
| Orlistat Intensive Lifestyle Mod. Intervention | n/r | n/r | n/r | n/r |
| Orlistat Standard Lifestyle Intervention | n/r | n/r | n/r | n/r |
| Orlistat Placebo | n/r | n/r | n/r | n/r |
| Orlistat Orlistat | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Low | 44.9% | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Top | 66.7% | n/r | n/r | n/r |
| Phentermine And Topiramate Placebo | 17.3% | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Top | 66% | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 Mid | 62.1% | n/r | n/r | n/r |
| Phentermine And Topiramate TPM 46 | 39.2% | n/r | n/r | n/r |
| Phentermine And Topiramate TPM 92 | 48.6% | n/r | n/r | n/r |
| Phentermine And Topiramate PHEN 7.5 | 43.3% | n/r | n/r | n/r |
| Phentermine And Topiramate PHEN 15 | 46.2% | n/r | n/r | n/r |
| Phentermine And Topiramate Placebo | 15.5% | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 12 | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 24 | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Phentermine & Topiramate | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Placebo Drugs | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Semaglutide | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Other anti-obesity medication | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | 0.05% | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | 55.6% | n/r | n/r |
| Setmelanotide Setmelanotide (Double-Blind) | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo (Double-Blind) | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide (Open-label) | n/r | n/r | n/r | n/r |
| Setmelanotide Pivotal Cohort | n/r | 32.3% | n/r | n/r |
| Setmelanotide 2 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 3 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 20 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 25 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 3 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 30 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 20 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 25 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 30 mg | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | 45.5% | n/r | n/r |
| Setmelanotide Setmelanotide | n/r | 80% | n/r | n/r |
| Setmelanotide Setmelanotide: PPL Group | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide: BBS Group | n/r | n/r | n/r | n/r |
| Setmelanotide 16p11.2 Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide AS Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide BBS Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide MC4R Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide SH2B1 Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide SMS Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide SRC1 Cohort | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 1: Setmelanotide (Open-Label) | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 2: Setmelanotide (Double-Blind) | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 2: Placebo (Double-Blind) | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide | 9.1% | n/r | n/r | n/r |
| Setmelanotide Placebo | 5.6% | n/r | n/r | n/r |
| Setmelanotide 0.5 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 1.5 mg | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo | n/r | n/r | n/r | n/r |
| Sibutramine Sibutramine | n/r | n/r | n/r | n/r |
| Sibutramine Placebo | n/r | n/r | n/r | n/r |
| Tesofensine placebo arm | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Semaglutide 1.0 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide placebo I/II: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo, in trial: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide placebo OW: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Semaglutide placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo, in trial: endpoint not reported
- Semaglutide Insuline glargine U100 (reduced) + semaglutide: endpoint not reported
- Semaglutide Insuline glargine U100 (titrated): endpoint not reported
- Semaglutide 7.2 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide 1.7 mg: endpoint not reported
- Semaglutide 1.7 mg: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Placebo, in trial: endpoint not reported
- Semaglutide Placebo: endpoint not reported
- Semaglutide 2.4 mg: endpoint not reported
- Semaglutide Semaglutide: endpoint not reported
- Semaglutide Placebo (semaglutide): endpoint not reported
- Tirzepatide 5 mg: endpoint not reported
- Tirzepatide 10 mg: endpoint not reported
- Tirzepatide Tirzepatide (lead-in): endpoint not reported
- Tirzepatide Tirzepatide: endpoint not reported
- Tirzepatide Placebo: endpoint not reported
- Tirzepatide Tirzepatide MTD_GPI1: endpoint not reported
- Tirzepatide Placebo_GPI1: endpoint not reported
- Tirzepatide Tirzepatide MTD_GPI2: endpoint not reported
- Tirzepatide Placebo_GPI2: endpoint not reported
- Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg: endpoint not reported
- Cagrilintide/semaglutide Placebo s.c.: endpoint not reported
- Retatrutide 4 mg: endpoint not reported
- Retatrutide 9 mg: endpoint not reported
- Retatrutide 12 mg: endpoint not reported
- Retatrutide Placebo: endpoint not reported
- Survodutide 3.6 mg: endpoint not reported
- Survodutide 6.0 mg: endpoint not reported
- Survodutide Placebo: endpoint not reported
- VK2735 2.5 mg: endpoint not reported
- VK2735 15 mg: endpoint not reported
- VK2735 Placebo 13 weeks: endpoint not reported
- Eloralintide Placebo: endpoint not reported
- Eloralintide 1 mg: endpoint not reported
- Eloralintide 3 mg: endpoint not reported
- Eloralintide 6 mg: endpoint not reported
- Eloralintide 9 mg: endpoint not reported
- Berobenatide Placebo: endpoint not reported
- Dulaglutide Dulaglutide Arm: endpoint not reported
- Dulaglutide Placebo Arm: endpoint not reported
- Exenatide Group A: endpoint not reported
- Exenatide Group B: endpoint not reported
- Exenatide Exenatide: endpoint not reported
- Exenatide Placebo: endpoint not reported
- Exenatide Exenatide once weekly (EQW ): endpoint not reported
- Exenatide Dapagliflozin (DAPA): endpoint not reported
- Exenatide EQW plus DAPA: endpoint not reported
- Exenatide Dapagliflozin plus Glucophage (MET ER): endpoint not reported
- Exenatide Phentermine /Topiramate (PHEN/ TPM) ER: endpoint not reported
- Exenatide Exenatide once weekly extended-release: endpoint not reported
- Exenatide Matching placebo: endpoint not reported
- Liraglutide 3.0mg: endpoint not reported
- Liraglutide 3.0mg: endpoint not reported
- Liraglutide Liraglutide Placebo, no Pre-diabetes: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide Semaglutide: endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo (liraglutide): endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide Metformin XR plus liraglutide: endpoint not reported
- Liraglutide Metformin XR plus placebo: endpoint not reported
- Liraglutide Liraglutide Pen Injector (Saxenda): endpoint not reported
- Liraglutide Placebo liraglutide pen injector: endpoint not reported
- Liraglutide Liraglutide: endpoint not reported
- Liraglutide Placebo: endpoint not reported
- Liraglutide Liraglutide + Metformin: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide 3.0 mg: endpoint not reported
- Liraglutide Orlistat: endpoint not reported
- Mazdutide 3/6 Milligrams (mg) Mazdutide: endpoint not reported
- Mazdutide 10 mg: endpoint not reported
- Mazdutide 16 mg: endpoint not reported
- Mazdutide Placebo: endpoint not reported
- Mazdutide 6 mg: endpoint not reported
- Oral Semaglutide Oral semaglutide: endpoint not reported
- Oral Semaglutide Oral semaglutide placebo: endpoint not reported
- Oral Semaglutide 25 mg: endpoint not reported
- Oral Semaglutide Oral semaglutide placebo: endpoint not reported
- Oral Semaglutide 50 mg: endpoint not reported
- Oral Semaglutide oral semaglutide placebo once daily: endpoint not reported
- TERN-601 250 mg: endpoint not reported
- TERN-601 500 mg: endpoint not reported
- TERN-601 750 mg: endpoint not reported
- TERN-601 Matching Placebo: endpoint not reported
- HM15211 HM15211: endpoint not reported
- HM15211 Placebo: endpoint not reported
- Pramlintide Placebo-P + Placebo-M: endpoint not reported
- Pramlintide 360 mcg: endpoint not reported
- Pramlintide 5.0 mg: endpoint not reported
- Pramlintide 2.5 mg: endpoint not reported
- Pramlintide 5.0 mg: endpoint not reported
- Pramlintide 1.25 mg: endpoint not reported
- Pramlintide 2.5 mg: endpoint not reported
- Pramlintide 5.0 mg: endpoint not reported
- Pramlintide 1: endpoint not reported
- Pramlintide 2: endpoint not reported
- Pramlintide 3: endpoint not reported
- Pramlintide Placebo: endpoint not reported
- Pramlintide Pramlintide + Metreleptin: endpoint not reported
- Pramlintide Pramlintide Acetate and Placebo: endpoint not reported
- Pramlintide Lead-In Period: endpoint not reported
- Naltrexone And Bupropion BWL + NB medication: endpoint not reported
- Naltrexone And Bupropion BWL + Placebo: endpoint not reported
- Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: endpoint not reported
- Naltrexone And Bupropion BWL + Placebo: endpoint not reported
- Naltrexone And Bupropion NB medication: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion Naltrexone+Bupropion Medication: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Naltrexone And Bupropion Naltrexone/Bupropion: endpoint not reported
- Naltrexone And Bupropion Placebo: endpoint not reported
- Orlistat Intensive Lifestyle Mod. Intervention: endpoint not reported
- Orlistat Standard Lifestyle Intervention: endpoint not reported
- Orlistat Placebo: endpoint not reported
- Orlistat Orlistat: endpoint not reported
- Phentermine And Topiramate LSMT 12: endpoint not reported
- Phentermine And Topiramate LSMT 24: endpoint not reported
- Phentermine And Topiramate Phentermine & Topiramate: endpoint not reported
- Phentermine And Topiramate Placebo Drugs: endpoint not reported
- Phentermine And Topiramate Semaglutide: endpoint not reported
- Phentermine And Topiramate Other anti-obesity medication: endpoint not reported
- Setmelanotide Setmelanotide: endpoint not reported
- Setmelanotide Setmelanotide (Double-Blind): endpoint not reported
- Setmelanotide Placebo (Double-Blind): endpoint not reported
- Setmelanotide Setmelanotide (Open-label): endpoint not reported
- Setmelanotide 2 mg: endpoint not reported
- Setmelanotide 2.5 mg: endpoint not reported
- Setmelanotide 3 mg: endpoint not reported
- Setmelanotide 20 mg: endpoint not reported
- Setmelanotide 25 mg: endpoint not reported
- Setmelanotide 3 mg: endpoint not reported
- Setmelanotide 30 mg: endpoint not reported
- Setmelanotide 20 mg: endpoint not reported
- Setmelanotide 25 mg: endpoint not reported
- Setmelanotide 30 mg: endpoint not reported
- Setmelanotide Setmelanotide: PPL Group: endpoint not reported
- Setmelanotide Setmelanotide: BBS Group: endpoint not reported
- Setmelanotide 16p11.2 Cohort: endpoint not reported
- Setmelanotide AS Cohort: endpoint not reported
- Setmelanotide BBS Cohort: endpoint not reported
- Setmelanotide MC4R Cohort: endpoint not reported
- Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort: endpoint not reported
- Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort: endpoint not reported
- Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort: endpoint not reported
- Setmelanotide SH2B1 Cohort: endpoint not reported
- Setmelanotide SMS Cohort: endpoint not reported
- Setmelanotide SRC1 Cohort: endpoint not reported
- Setmelanotide Stage 1: Setmelanotide (Open-Label): endpoint not reported
- Setmelanotide Stage 2: Setmelanotide (Double-Blind): endpoint not reported
- Setmelanotide Stage 2: Placebo (Double-Blind): endpoint not reported
- Setmelanotide Placebo: endpoint not reported
- Setmelanotide 0.5 mg: endpoint not reported
- Setmelanotide 1.5 mg: endpoint not reported
- Setmelanotide 2.5 mg: endpoint not reported
- Setmelanotide Placebo: endpoint not reported
- Sibutramine Sibutramine: endpoint not reported
- Sibutramine Placebo: endpoint not reported
- Tesofensine placebo arm: endpoint not reported
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.